SCHEMBL19055368

SCHEMBL19055368

CCCC(C)OCc1c(Cl)cccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ POLB P06746 3/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ HPGD P15428 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.35
▸ KMT2A Q03164 3/20 0.35
▸ TAAR1 Q96RJ0 1/20 0.34
▸ MCHR1 Q99705 1/20 0.34
▸ MEN1 O00255 1/20 0.33
▸ USP2 O75604 1/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ CYP2D6 P10635 1/20 0.33
▸ CYP2C9 P11712 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CYP2C19 P33261 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19099368 0.89 TAAR1 (0.44) SMN1; SMN2ALDH1A1HPGDKMT2ATAAR1
SCHEMBL19098853 0.88 SMN1; SMN2 (0.38) SMN1; SMN2POLBALDH1A1KDM4EKMT2A
SCHEMBL19055367 0.85 SMN1; SMN2 (0.41) SMN1; SMN2POLBALDH1A1HPGDKDM4E
SCHEMBL19055334 0.85 P2RX7 (0.37) SMN1; SMN2POLBALDH1A1HPGDKMT2A
SCHEMBL21466573 0.81 IDO1 (0.47) ALDH1A1HPGDKDM4ETAAR1LMNA
SCHEMBL19098941 0.80 SMN1; SMN2 (0.40) SMN1; SMN2POLBALDH1A1HPGDKDM4E
SCHEMBL20091122 0.80 KMT2A (0.48) SMN1; SMN2ALDH1A1HPGDKMT2ATAAR1
SCHEMBL16708451 0.79 SMN1; SMN2 (0.44) SMN1; SMN2POLBALDH1A1HPGDKDM4E
SCHEMBL19098822 0.78 KMT2A (0.43) SMN1; SMN2ALDH1A1KMT2ATAAR1MEN1
SCHEMBL5667835 0.76 SMN1; SMN2 (0.42) SMN1; SMN2POLBALDH1A1HPGDKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10442798-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-10-15 — — US disclosed
US-10364237-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-07-30 — — US disclosed
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2019-01-29 — — US disclosed
US-20180208587-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE LYCERA CORPORATION 2018-07-26 — — US disclosed
US-9896441-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease LYCERA CORPORATION (US) 2018-02-20 — — US disclosed
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-07-06 — — US disclosed
US-20170183331-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE WILMINGTON TRUST, NATIONAL ASSOCIATION 2017-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10364237-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORA, RORC, RORB SMN1; SMN2 2195/4885POLB 4519/4885ALDH1A1 762/4885
US-10189777-B2 Benzenesulfonamido and related compounds for use as agonists of RORγ and the treatment of disease RORC, RORB, RORA SMN1; SMN2 2811/4885POLB 3653/4885ALDH1A1 681/4885
US-10442798-B2 Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease RORA, RORC, RORB SMN1; SMN2 2195/4885POLB 4519/4885ALDH1A1 762/4885
US-20170190659-A1 BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORB, RORA, RORC SMN1; SMN2 3028/4885POLB 2985/4885ALDH1A1 665/4885
US-20170183331-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORA, RORB, RORC SMN1; SMN2 1570/4885POLB 4352/4885ALDH1A1 602/4885
US-20180208587-A1 TETRAHYDROQUINOLINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORy AND THE TREATMENT OF DISEASE RORA, RORB, RORC SMN1; SMN2 1570/4885POLB 4352/4885ALDH1A1 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback